 In patients responding insufficiently to MTX andor other synthetic DMARDs with or without GCs, biological DMARDs should be started 1; current practice would be to start a TNF inhibitor adalimumab, certolizumab, etanercept, golimumab or infliximab which should be combined with MTX. 